Solara Active Pharma Q1 FY27 call set for July 23, 2026

What the company has scheduled

Solara Active Pharma Sciences has scheduled a conference call on July 23, 2026 at 4:00 PM IST to discuss its unaudited financial results for the quarter ended June 30, 2026. The company said the meeting is meant for investors and analysts. It will provide a platform to review quarterly performance and take questions from the market. The company also shared dial-in details and a link for early registration to facilitate entry into the call. The announcement comes as Solara enters its Q1 FY27 results cycle after reporting a turnaround in profitability in Q4 FY26 on a consolidated basis. The conference call format suggests management intends to provide a structured update on numbers, operating drivers, and outlook items that are typically discussed during results interactions.

Who will speak on the call

The company said the call will be led by Sandeep Rao, Managing Director and CEO, along with Sarat Kumar, Chief Financial Officer. The presence of both the CEO and CFO indicates the discussion is likely to include both operational updates and financial drivers such as margins, costs, and balance sheet items. For analyst and institutional investors, management commentary can help bridge the gap between the headline numbers and underlying factors. Solara has positioned the call as an investor and analyst interaction, consistent with standard disclosure practices around quarterly results. The company has not, in the provided information, shared the detailed agenda beyond discussion of the unaudited quarter results.

Dial-in and access details shared by Solara

As part of the investor communication, Solara shared universal access numbers for participants. It also mentioned an early registration link to streamline entry into the call. These are common measures used to avoid call congestion and ensure participants can join on time. Participants typically use the registration link to receive unique dial-in credentials or a streamlined access path. The company’s communication includes the following universal access numbers.

Context: FY26 audited results were approved in May

Before the upcoming Q1 FY27 discussion, Solara had announced its audited financial results for the quarter and year ended March 31, 2026. The Board of Directors approved these results at a meeting held on May 15, 2026. The company also published an extract of the audited financial results (standalone and consolidated) for the year ended March 31, 2026, along with unaudited financial results for the quarter ended March 31, 2026, through a newspaper advertisement in Business Standard and Pratahkal on May 16, 2026. These disclosures set the baseline for how investors may evaluate the next quarter’s numbers, particularly on profitability and revenue trajectory.

Q4 FY26: return to profit, revenue up sharply

On a consolidated basis, Solara reported a net profit of ₹9.60 crore for the quarter ended March 31, 2026 (Q4 FY26). This compared with a net loss of ₹2.10 crore in the corresponding quarter of the previous year. Revenue from operations for the quarter stood at ₹387.29 crore, described as a 40% year-on-year increase. The company also reported EBITDA of ₹61 crore for the quarter. Together, these figures suggest Q4 FY26 marked a stronger quarter on both growth and operating profitability metrics versus the prior-year period. The upcoming Q1 FY27 call will be watched for whether this profitability level sustained into the quarter ended June 30, 2026.

FY26: revenue growth but a full-year net loss

For the full financial year ended March 31, 2026, Solara reported a net loss of ₹7.41 crore on a consolidated basis. This compares to a net profit of ₹0.54 crore in the previous year. Revenue from operations for the year rose to ₹1,368.98 crore from ₹1,283.76 crore, while total income stood at ₹1,375.14 crore. The contrast of higher annual revenue but a net loss highlights that cost structure, finance costs, exceptional items, or other profit drivers remained important through the year. Investors typically look for clarity on what changed quarter to quarter, and whether the March quarter improvement represents a structural shift or a period-specific outcome.

Trading window closure and earnings cycle signals

A market snapshot included in the provided information noted that Solara is preparing to announce its first-quarter results for FY26-27 (Q1 FY27). It also stated that the company’s trading window has been closed since July 1, 2026 in anticipation of the board’s review. Such closures are standard compliance practice around results and unpublished price sensitive information. The same snapshot referenced the July 23, 2026 earnings call time as stated in the source alert. For shareholders, these process markers usually indicate that results review and related corporate formalities are in progress.

Stock and market data points cited in the snapshot

The provided data included multiple price references for Solara Active Pharma Sciences. One snapshot showed a price of ₹585.40, up ₹16.50 (2.90%), with an NSE timestamp of July 13 at 4:00 PM. Another section mentioned “current price” as ₹570.15, while a separate block listed “Current Price ₹576” along with market cap of ₹2,750 crore and a 52-week high/low of ₹734/₹422. These figures appear to come from different market snapshots and should be read as point-in-time references from the provided material rather than a single synchronized quote. The company’s listings were noted as NSE: SOLARA and BSE: 541540, with sector tagged as Pharmaceuticals and Drugs.

Quarterly financial trend: recent five-quarter series

The provided quarterly table showed a series from March 2025 through March 2026 with net sales, expenditure, operating profit, and profit before tax (PBT). Net sales rose from ₹273.01 crore in March 2025 to ₹387.29 crore in March 2026, while PBT moved from a loss in March 2025 to a profit in March 2026. The same table showed exceptional items in December 2025 at -₹6.75 crore and in March 2026 at ₹0.86 crore. Interest and depreciation remained sizable line items across quarters, which can materially influence net outcomes even when operating profit improves.

Additional disclosed operating metrics and balance sheet markers

Separate result highlights in the provided material included a Q2 FY26 update stating revenue at ₹314.0 crore versus ₹347.2 crore in Q2 FY25, a 10% year-on-year decline. The same update stated Q2 FY26 EBITDA at ₹35.2 crore (11.3%) versus ₹61.5 crore (17.7%) in Q2 FY25 and ₹57.5 crore (18%) in Q1 FY26. It also mentioned gross debt as of September 30, 2025 at ₹623.3 crore compared with ₹776.0 crore at the end of FY25, implying a reduction of ₹152.7 crore. Another provided block for Q1 FY26 stated gross debt reduced by ₹1,433 crore to ₹6,327 crore as of June 30, 2025, and noted a rights issue raised ₹306.97 crore (₹449.95 crore total, ₹134.99 crore pending), along with a planned CRAMS/Polymers business demerger into a new entity named Synthix Global Pharma Solutions. These historical disclosures are part of the broader context investors may use when assessing leverage, cash flows, and corporate structure developments.

Credit rating upgrade mentioned ahead of Q1 FY27

The provided information also stated that Solara is entering its Q1 FY27 earnings cycle backed by turnaround momentum and a credit rating upgrade to ‘BBB+/A2’ by CRISIL. While the material did not include the date of this rating action or the rationale, a rating upgrade typically draws attention to leverage metrics, profitability improvement, liquidity, and business risk profile. Investors often look for management commentary on how the company plans to sustain improvements that support such rating outcomes.

Why the July 23 call matters for investors

The July 23, 2026 call is the first formal management interaction in FY27 around performance for the quarter ended June 30, 2026. With Q4 FY26 showing a return to consolidated profit and FY26 closing with a net loss, the near-term question for the market is whether profitability is stabilising quarter to quarter. The disclosed quarterly table indicates that operating profit can be meaningfully offset by interest and depreciation, making financing costs and capacity utilisation key areas to track. The call also provides a timely forum for clarifications around revenue mix, operating margin movement, and any updates relevant to debt and business restructuring already referenced in earlier disclosures.

Conclusion

Solara Active Pharma Sciences will hold its Q1 FY27 earnings conference call on July 23, 2026 at 4:00 PM IST to discuss unaudited results for the quarter ended June 30, 2026, with the MD and CEO and CFO expected to lead the discussion. The company enters the quarter after reporting a consolidated profit of ₹9.60 crore in Q4 FY26 and FY26 revenue of ₹1,368.98 crore alongside a full-year net loss of ₹7.41 crore. The next confirmed step in the process is the scheduled investor and analyst call, for which the company has already shared dial-in access and an early registration option.